ArticleFrontiers in oncology2026
Primary testicular neuroendocrine tumor with retroperitoneal lymph nodes metastasis: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testicular neuroendocrine tumor (TNET) is an exceedingly rare malignancy with variable biological behavior. We report a 49-year-old male presenting with painless right testicular enlargement. Primary TNET (G1) was diagnosed after extensive pathological sampling and the clinical exclusion of extra-testicular primary sites via contrast-enhanced CT. Following radical orchiectomy, the patient underwent laparoscopic retroperitoneal lymph node dissection (RPLND), which confirmed metastatic involvement (7/13 nodes). Although severe intraoperative adhesions to the great vessels were encountered, a thorough dissection was performed, and postoperative imaging showed no measurable macroscopic residual disease, consistent with a clinical R0 resection. Based on a multidisciplinary team (MDT) assessment of the high risk for subclinical microscopic residuals, adjuvant therapy with surufatinib, a multi-targeted TKI, was initiated. A complete response (CR) was achieved eight months postoperatively, defined by the disappearance of all target lesions on follow-up contrast-enhanced CT according to RECIST 1.1 criteria. The patient remains disease-free at the one-year follow-up, suggesting that targeted therapy may be a promising and effective option for metastatic G1 TNET following surgical debulking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.